TP53 and glioblastoma: The wild type TP53 AGII cases (Figure 4A–4C) showed weak or no staining for the three targets in comparison to the TP53-mutated cases (Figure 4D–4F), as did the primary GBM cases (Figure 4G–4I) when compared to the secondary GBM (Figure 4J–4L) cases.